Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 329.55 INR -1.91% Market Closed
Market Cap: 394.7B INR
Have any thoughts about
Biocon Ltd?
Write Note
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

148.9B
+0.9%
Revenue
Growth Rates:
1 Year
+10%
3 Years
+103%
5 Years
+144%
7 Years
+284%
10 Years
+410%
15B
-5%
Operating Income
Growth Rates:
1 Year
-11%
3 Years
+65%
5 Years
+32%
7 Years
+191%
10 Years
+208%
14.4B
-9%
Net Income
Growth Rates:
1 Year
+189%
3 Years
+123%
5 Years
+69%
7 Years
+221%
10 Years
+240%

Earnings Waterfall
Biocon Ltd

Revenue
148.9B INR
Cost of Revenue
-49.3B INR
Gross Profit
99.7B INR
Operating Expenses
-84.7B INR
Operating Income
15B INR
Other Expenses
-625m INR
Net Income
14.4B INR

Income Statement
Biocon Ltd

Rotate your device to view
Income Statement
Currency: INR
Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
29 187
N/A
29 806
+2%
30 898
+4%
31 855
+3%
32 241
+1%
32 620
+1%
33 810
+4%
35 520
+5%
37 099
+4%
39 472
+6%
39 216
-1%
38 633
-1%
38 778
+0%
38 913
+0%
41 297
+6%
43 198
+5%
46 722
+8%
51 551
+10%
55 144
+7%
58 495
+6%
60 958
+4%
62 718
+3%
63 005
+0%
65 354
+4%
66 904
+2%
68 585
+3%
71 431
+4%
72 099
+1%
73 280
+2%
76 173
+4%
81 840
+7%
85 629
+5%
90 422
+6%
98 091
+8%
111 742
+14%
124 573
+11%
135 999
+9%
146 125
+7%
147 557
+1%
147 660
+0%
148 941
+1%
Gross Profit
Cost of Revenue
(11 884)
(12 112)
(14 837)
(12 935)
(13 099)
(12 954)
(15 725)
(13 957)
(14 232)
(14 948)
(17 089)
(14 427)
(14 665)
(15 156)
(19 114)
(17 105)
(17 796)
(18 839)
(22 444)
(18 805)
(19 076)
(19 271)
(23 624)
(21 345)
(21 709)
(22 151)
(26 518)
(22 930)
(23 479)
(24 690)
(32 055)
(28 091)
(29 959)
(32 626)
(43 504)
(41 699)
(45 450)
(47 972)
(54 845)
(48 710)
(49 266)
Gross Profit
17 303
N/A
17 694
+2%
16 061
-9%
18 919
+18%
19 141
+1%
19 665
+3%
18 085
-8%
21 563
+19%
22 867
+6%
24 524
+7%
22 127
-10%
24 206
+9%
24 113
0%
23 757
-1%
22 183
-7%
26 093
+18%
28 926
+11%
32 712
+13%
32 700
0%
39 690
+21%
41 882
+6%
43 447
+4%
39 381
-9%
44 009
+12%
45 195
+3%
46 434
+3%
44 913
-3%
49 169
+9%
49 801
+1%
51 483
+3%
49 785
-3%
57 538
+16%
60 463
+5%
65 465
+8%
68 238
+4%
82 874
+21%
90 549
+9%
98 153
+8%
92 712
-6%
98 950
+7%
99 675
+1%
Operating Income
Operating Expenses
(12 435)
(12 998)
(10 980)
(13 904)
(14 233)
(14 648)
(12 799)
(15 905)
(13 889)
(14 697)
(15 081)
(18 220)
(18 957)
(19 416)
(17 742)
(21 199)
(22 367)
(24 708)
(23 241)
(28 485)
(30 517)
(31 768)
(28 859)
(34 168)
(35 873)
(37 909)
(35 463)
(40 312)
(40 694)
(41 756)
(37 928)
(46 654)
(49 623)
(54 018)
(51 977)
(67 143)
(73 694)
(79 607)
(74 878)
(83 065)
(84 658)
Selling, General & Administrative
(4 988)
(5 193)
(7 851)
(5 562)
(5 639)
(5 801)
(9 632)
(6 403)
(6 776)
(7 196)
(11 731)
(7 818)
(8 269)
(8 680)
(14 999)
(9 792)
(10 426)
(11 017)
(19 886)
(12 449)
(13 093)
(13 910)
(23 524)
(15 115)
(15 901)
(16 773)
(27 628)
(17 833)
(18 302)
(18 619)
(29 209)
(19 567)
(20 182)
(20 820)
(38 203)
(22 477)
(23 298)
(24 918)
(53 418)
(28 402)
(30 074)
Research & Development
0
0
(2 000)
0
0
0
(1 715)
0
0
0
(1 492)
0
0
0
(358)
0
0
0
(1 396)
0
0
0
(3 077)
0
0
0
(3 950)
0
0
0
(5 028)
0
0
0
(6 132)
0
0
0
(6 071)
0
0
Depreciation & Amortization
(2 114)
(2 164)
(2 210)
(2 281)
(2 349)
(2 425)
(2 487)
(2 558)
(2 631)
(2 695)
(2 772)
(3 099)
(3 352)
(3 623)
(3 850)
(3 854)
(4 040)
(4 233)
(4 478)
(4 729)
(4 923)
(5 196)
(5 522)
(5 948)
(6 409)
(6 832)
(7 151)
(7 431)
(7 669)
(7 863)
(8 142)
(8 369)
(8 662)
(9 616)
(11 131)
(12 536)
(14 121)
(15 255)
(15 688)
(16 162)
(16 468)
Other Operating Expenses
(5 333)
(5 640)
1 081
(6 060)
(6 244)
(6 422)
1 035
(6 944)
(4 482)
(4 806)
914
(7 303)
(7 336)
(7 113)
1 465
(7 553)
(7 901)
(9 458)
2 519
(11 307)
(12 501)
(12 662)
3 264
(13 105)
(13 563)
(14 304)
3 266
(15 048)
(14 723)
(15 274)
4 451
(18 718)
(20 779)
(23 582)
3 489
(32 130)
(36 275)
(39 434)
299
(38 501)
(38 116)
Operating Income
4 869
N/A
4 697
-4%
5 081
+8%
5 016
-1%
4 909
-2%
5 018
+2%
5 286
+5%
5 658
+7%
8 978
+59%
9 827
+9%
7 046
-28%
5 986
-15%
5 156
-14%
4 341
-16%
4 441
+2%
4 894
+10%
6 559
+34%
8 004
+22%
9 459
+18%
11 205
+18%
11 365
+1%
11 679
+3%
10 522
-10%
9 841
-6%
9 322
-5%
8 525
-9%
9 450
+11%
8 857
-6%
9 107
+3%
9 727
+7%
11 857
+22%
10 884
-8%
10 840
0%
11 447
+6%
16 261
+42%
15 731
-3%
16 855
+7%
18 546
+10%
17 834
-4%
15 885
-11%
15 017
-5%
Pre-Tax Income
Interest Income Expense
(66)
(96)
(62)
(89)
32
76
494
(73)
(163)
(254)
1 322
(214)
(274)
(279)
1 479
(453)
1 317
1 399
2 651
1 251
(578)
(752)
913
(644)
(535)
(503)
(488)
(1 970)
(2 672)
(3 146)
(1 198)
(2 614)
(2 466)
(3 606)
(6 533)
(7 893)
(10 029)
(11 178)
(3 541)
(10 284)
(9 821)
Non-Reccuring Items
0
0
1 051
1 051
(27)
0
1 606
1 606
0
0
0
0
0
0
0
0
0
0
0
0
675
675
675
675
0
0
1 723
126
(575)
(575)
(812)
(1 111)
(580)
(3 294)
(744)
(2 914)
(2 984)
249
937
511
1 011
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(11)
0
0
0
(73)
0
0
0
(23)
0
0
0
(52)
0
0
0
(12)
0
0
Total Other Income
612
535
171
568
645
815
127
1 012
1 169
1 427
129
1 702
1 826
1 691
180
2 210
1 968
1 837
39
997
1 115
1 265
50
1 556
1 271
1 122
65
2 834
3 784
4 058
7
2 984
2 580
2 883
39
3 915
4 849
9 411
34
18 758
17 504
Pre-Tax Income
5 416
N/A
5 136
-5%
6 241
+22%
6 546
+5%
5 559
-15%
5 909
+6%
7 513
+27%
8 203
+9%
9 984
+22%
11 000
+10%
8 497
-23%
7 474
-12%
6 708
-10%
5 753
-14%
6 100
+6%
6 651
+9%
9 844
+48%
11 240
+14%
12 149
+8%
13 453
+11%
12 577
-7%
12 867
+2%
12 149
-6%
11 428
-6%
10 058
-12%
9 144
-9%
10 677
+17%
9 847
-8%
9 644
-2%
10 064
+4%
9 831
-2%
10 143
+3%
10 374
+2%
7 430
-28%
8 971
+21%
8 839
-1%
8 691
-2%
17 028
+96%
15 252
-10%
24 870
+63%
23 711
-5%
Net Income
Tax Provision
(980)
(830)
(957)
(1 024)
(1 088)
(1 194)
(1 422)
(1 598)
(1 733)
(2 059)
(1 616)
(1 440)
(1 448)
(1 265)
(1 569)
(1 714)
(2 021)
(2 121)
(2 123)
(2 454)
(2 723)
(3 110)
(3 151)
(3 108)
(2 330)
(1 971)
(2 215)
(1 979)
(2 219)
(2 223)
(2 115)
(1 837)
(2 847)
(2 306)
(2 541)
(2 594)
(1 537)
(2 134)
(2 274)
(4 763)
(5 060)
Income from Continuing Operations
4 436
4 307
5 284
5 522
4 471
4 714
6 091
6 605
8 251
8 941
6 881
6 034
5 260
4 488
4 531
4 937
7 823
9 119
10 026
10 999
9 854
9 757
8 998
8 320
7 728
7 173
8 462
7 868
7 425
7 841
7 716
8 306
7 527
5 124
6 430
6 245
7 154
14 894
12 978
20 107
18 651
Income to Minority Interest
(205)
(217)
(310)
(339)
(414)
(525)
(587)
(674)
(747)
(765)
(760)
(766)
(771)
(793)
(807)
(829)
(856)
(899)
(973)
(1 001)
(1 152)
(1 167)
(1 227)
(1 197)
(1 077)
(982)
(1 057)
(1 113)
(1 066)
(1 211)
(1 232)
(1 222)
(1 357)
(1 243)
(1 803)
(2 048)
(2 170)
(2 892)
(2 753)
(4 299)
(4 259)
Net Income (Common)
4 232
N/A
4 091
-3%
4 974
+22%
5 184
+4%
4 057
-22%
4 189
+3%
5 504
+31%
5 931
+8%
7 504
+27%
8 176
+9%
6 121
-25%
5 268
-14%
4 489
-15%
3 695
-18%
3 724
+1%
4 108
+10%
6 967
+70%
8 220
+18%
9 053
+10%
9 919
+10%
8 529
-14%
8 385
-2%
7 482
-11%
6 913
-8%
6 449
-7%
6 107
-5%
7 405
+21%
6 755
-9%
6 445
-5%
6 630
+3%
6 484
-2%
7 084
+9%
6 170
-13%
3 881
-37%
4 627
+19%
4 197
-9%
4 984
+19%
12 002
+141%
10 225
-15%
15 808
+55%
14 392
-9%
EPS (Diluted)
3.53
N/A
3.36
-5%
4.14
+23%
4.4
+6%
3.44
-22%
3.55
+3%
4.67
+32%
5.03
+8%
6.23
+24%
6.88
+10%
5.16
-25%
4.43
-14%
3.78
-15%
3.12
-17%
3.14
+1%
3.46
+10%
5.77
+67%
6.97
+21%
7.6
+9%
8.36
+10%
7.19
-14%
7.06
-2%
6.3
-11%
5.78
-8%
5.28
-9%
5.15
-2%
6.19
+20%
5.68
-8%
5.4
-5%
5.52
+2%
5.42
-2%
5.92
+9%
5.12
-14%
3.24
-37%
3.87
+19%
3.51
-9%
4.17
+19%
10.03
+141%
8.54
-15%
13.2
+55%
11.69
-11%

See Also

Summary
BIOCON intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIOCON stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIOCON stock valuation using valuation multiples.
Wall Street Estimates
BIOCON price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIOCON stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.